Skip to main content
Equibles

TLSA · Tiziana Life Sciences Ltd · Documents

Track TLSA — free

Use TLSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TLSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.61 -0.01 (-1.69%) At close · Nov 12
Rebalance outlook locked
Market Cap
$77.69M
Shares
127.26M
Volume · Nov 12 194.48K Avg daily vol (3M) 705.84K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Diluted EPS -$0.16 20-F filed May 1, 2026
2026
Nov 9
Current report 6-K
BIO-Europe presentation and webcast highlight positive foralumab results

Tiziana Life Sciences will present at BIO-Europe 2026 on November 10, 2026, and host a November 9, 2026 Key Opinion Leader webcast about positive Phase 2a INFORM-MS topline results for intranasal foralumab in na-SPMS.

3 source passages
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Tiziana is also hosting a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS. Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, will deliver a company presentation at BIO-Europe in the Presenting Companies track (Theater A) on Tuesday, November 10, 2026, from 13:45 local time. Open the document at this passage
Nov 5
Current report 6-K
INFORM-MS met primary endpoint with significant microglial reduction

Tiziana Life Sciences said its Phase 2a INFORM-MS trial of intranasal foralumab met its primary endpoint in the 50μg arm (p=0.0168), with significant fatigue improvements at both doses after 12 weeks.

3 source passages
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will host a conference call and webcast with Key Opinion Leaders (KOLs) to discuss the positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). The primary endpoint reaching a statistically significant reduction in microglial activation measured by [¹⁸F]PBR06 TSPO PET imaging in the 50 μg nasal foralumab arm versus placebo (p=0.0168) Despite the short treatment duration of only 12 weeks, patients in both foralumab dose arms experienced clinically significant and statistically significant improvements in fatigue, a common and debilitating symptom of progressive MS. Open the document at this passage
Nov 2
Current report 6-K/A
Original report incorporated into registration statements

Tiziana Life Sciences LTD amended its original report solely to incorporate that report and Exhibit 99.1 by reference into its registration statements.

Source passage
This Amendment No. 1 on Form 6-K/A (this “Amendment”) amends the Report on Form 6-K furnished by Tiziana Life Sciences LTD to the Securities and Exchange Commission (the “SEC”) on October 16, 2026 (the “Original Form 6-K”) solely to provide that the information contained in the Original Form 6-K, including Exhibit 99.1 thereto, is incorporated by reference into the Company’s Registration Statement on [Form F-3]( (Reg. No. 333-286064) and [Form S-8]( (Reg. No. 333-293620). Open the document at this passage
Nov 2
Current report 6-K
Phase 2a trial meets dual endpoints in multiple sclerosis

Tiziana Life Sciences reported that its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis met dual primary endpoints, including reduced microglial activation at 50 ug versus placebo (p=0.0168) and fatigue improvement after 12 weeks.

3 source passages
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced positive topline data in its Phase 2a INFORM-MS trial with intranasal foralumab (a human, anti-CD3 monoclonal antibody) in patients with non-active secondary progressive multiple sclerosis (na-SPMS). Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as compared to placebo and (2) safety/tolerability Foralumab-treated subjects showed statistically significant and clinically significant improvements in Modified Fatigue Impact Scale (MFIS) scores compared with their own baseline scores after only 12 weeks of drug therapy. Open the document at this passage
Oct 21
Current report 6-K
Current report

Tiziana Life Sciences said 14 patients with na-SPMS dosed with intranasal foralumab showed improvement or stability within 6 months; its team will attend MSToronto2026, held October 21–23, 2026.

Oct 16
Current report 6-K
Current report

Tiziana Life Sciences Ltd reported a $12.4 million comprehensive loss and $3.2 million cash; disclosed material uncertainty over meeting liabilities within 12 months; and expects Phase 2 INFORM-MS topline data in Q4 2026.

Read from the first part of this long document
Oct 16
Current report 6-K
Current report

Tiziana Life Sciences announced the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early/mild Alzheimer's disease, with topline data anticipated in Q1 2027.

Sep 30
Current report 6-K
Current report

Tiziana Life Sciences submitted a request on September 30, 2026, for Orphan Drug Designation of intranasal foralumab to treat Multiple System Atrophy. The company is evaluating the candidate in a six-month Phase 2a open-label trial.

Sep 28
Current report 6-K
Current report

Tiziana Life Sciences announced that the first three participants received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial on September 28, 2026.

Sep 21
Current report 6-K
Current report

Tiziana Life Sciences said the last patient completed their last visit in the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS; it expects database lock this week and topline data in October.

2025
Showing 1–50 of 353 documents
Key facts CIK 1723069 CUSIP G88912103 13F (30d) 26 filings 20 filers Visit website Investor relations